GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (STU:MBP) » Definitions » 12-1 Month Momentum %

Protagenic Therapeutics (STU:MBP) 12-1 Month Momentum % : -20.66% (As of Apr. 11, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Protagenic Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-11), Protagenic Therapeutics's 12-1 Month Momentum % is -20.66%.

The industry rank for Protagenic Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

STU:MBP's 12-1 Month Momentum % is ranked worse than
90.41% of 1449 companies
in the Biotechnology industry
Industry Median: -23.43 vs STU:MBP: -20.66

Competitive Comparison of Protagenic Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Protagenic Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's 12-1 Month Momentum % falls into.


;
;

Protagenic Therapeutics  (STU:MBP) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protagenic Therapeutics  (STU:MBP) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Protagenic Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics Headlines

No Headlines